[1]马 燕,王晓忠,延国威,等.乙肝肝硬化低血钠症患者血清钠、肌酐以及胱抑素C与肾功能损害程度的关系[J].医学信息,2020,33(19):55-58.[doi:10.3969/j.issn.1006-1959.2020.19.017]
　MA Yan,WANG Xiao-zhong,YAN Guo-wei,et al.The Relationship Between Serum Sodium,Creatinine,Cystatin C and the Degree of Renal Damage in Patients with Hepatitis B Liver Cirrhosis and Hyponatremia[J].Medical Information,2020,33(19):55-58.[doi:10.3969/j.issn.1006-1959.2020.19.017]
点击复制

乙肝肝硬化低血钠症患者血清钠、肌酐以及胱抑素C与肾功能损害程度的关系()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年19期
页码:
55-58
栏目:
论著
出版日期:
2020-10-01

文章信息/Info

Title:
The Relationship Between Serum Sodium,Creatinine,Cystatin C and the Degree of Renal Damage in Patients with Hepatitis B Liver Cirrhosis and Hyponatremia
文章编号:
1006-1959（2020）19-0055-04
作者:
马 燕; 王晓忠; 延国威; 何 倩; 郭 峰; 王宏峰
新疆医科大学附属中医医院肝病科，新疆 乌鲁木齐 830000
Author(s):
MA Yan; WANG Xiao-zhong; YAN Guo-wei; HE Qian; GUO Feng; WANG Hong-feng
Department of Liver Diseases,the Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000,Xinjiang,China
关键词:
乙肝肝硬化; 肾损害; 低钠血症; 肌酐; 胱抑素C
Keywords:
Hepatitis B cirrhosis; Kidney damage; Hyponatremia; Creatinine; Cystatin C
分类号:
R512.62；R575.2；R692
DOI:
10.3969/j.issn.1006-1959.2020.19.017
文献标志码:
A
摘要:
目的 观察乙肝肝硬化低血钠症患者血清钠、肌酐以及胱抑素C与肾功能损害程度的关系。方法 选择2017年1月~2019年12月我院收治的387例乙肝肝硬化低血钠症患者，通过肾小球滤过率（eGFR）评估患者肾功能，观察肾功能损害发生率，并分为肾功能损害组[eGFR＜60 ml/（min·1.73）m2]和肾功能正常组[eGFR≥60 ml/（min·1.73）m2）]；比较两组血清钠、肌酐以及胱抑素C水平，观察三者与乙肝肝硬化患者肾功能损害严重程度的关系。结果 共80例患者出现肾功能损害，肾功能损害发生率20.67%；肾功能损害组eGFR、Na+水平低于肾功能正常组，Scr和CysC水平高于肾功能正常组，差异有统计学意义（P＜0.05）；乙肝肝硬化低血钠患者eGFR与血清Na+呈正相关（r=0.252，P＜0.05），与Scr、CysC水平呈负相关（r=-0.284、-0.427，P＜0.05）；ROC曲线分析显示，血清Na+水平诊断乙肝肝硬化低血钠患者肾功能损害的灵敏度、特异性为83.20%和72.90%，最佳截断值为126.47 mmol/L；Scr水平诊断乙肝肝硬化低血钠患者肾功能损害的灵敏度、特异性为83.80%和87.00%，最佳截断值值为113.28 μmol/L，Cys-C水平诊断乙肝肝硬化低血钠患者肾功能损害的灵敏度、特异性为88.80%和85.80%，最佳截断值值为2.73 mg/L；三者联合诊断乙肝肝硬化低血钠患者肾功能损害的灵敏度、特异性为95.00%和97.90%。结论 乙肝肝硬化低钠血症患者肾功能损害发生率较高，且与血清Na+、Scr、CysC水平密切相关，三者均有较高的临床诊断价值，且三者联合检测可提高乙肝肝硬化低钠血症患者肾功能损害诊断的准确性和灵敏性。
Abstract:
Objective To observe the relationship between serum sodium, creatinine, cystatin C and the degree of renal damage in patients with hepatitis B liver cirrhosis and hyponatremia.Methods 387 patients with hepatitis B cirrhosis and hyponatremia admitted to our hospital from January 2017 to December 2019 were selected. The renal function of the patients was evaluated by the glomerular filtration rate (eGFR), and the incidence of renal damage was observed and divided Renal function impairment group [eGFR＜60 ml/(min·1.73)m2] and normal renal function group [eGFR≥60 ml/(min·1.73)m2)]; compare the two groups’ serum sodium, creatinine and cystatin C levels,observe the relationship between the three and the severity of renal damage in patients with hepatitis B and cirrhosis.Results A total of 80 patients had renal dysfunction, and the incidence of renal dysfunction was 20.67%; the eGFR and Na+ levels of the renal dysfunction group were lower than those of the normal renal function group, and the levels of Scr and Cys-C were higher than those of the normal renal function group,the difference was statistically significant (P＜0.05); eGFR in patients with hepatitis B liver cirrhosis and hyponatremia was positively correlated with serum Na+ (r=0.252,P＜0.05), and negatively correlated with Scr and Cys-C levels (r=-0.284, -0.427,P＜0.05); ROC curve analysis showed that the sensitivity and specificity of serum Na+ level in diagnosing renal damage in patients with hepatitis B cirrhosis and hyponatremia were 83.20% and 72.90%, and the best cut-off value was 126.47 mmol/L; Scr level was used to diagnose patients with hepatitis B cirrhosis and hyponatremia. The sensitivity and specificity of renal impairment were 83.80% and 87.00%, and the best cut-off value was 113.28 μmol/L. The sensitivity and specificity of Cys-C level in diagnosing renal impairment in patients with hepatitis B cirrhosis and hyponatremia were 88.80% and 85.80%, the best cut-off value was 2.73 mg/L; the sensitivity and specificity of the three combined diagnosis of renal damage in patients with hepatitis B cirrhosis and hyponatremia were 95.00% and 97.90%.Conclusion The incidence of renal dysfunction in patients with hepatitis B cirrhosis and hyponatremia was higher, and it was closely related to serum Na+, Scr, and Cys-C levels. The three had high clinical diagnostic value, and the combined detection of the three could improve hepatitis B cirrhosis accuracy and sensitivity of the diagnosis of renal impairment in patients with hyponatremia.

参考文献/References:

[1]贾继东,侯金林,魏来,等.《慢性乙型肝炎防治指南(2019年版)》新亮点[J].中华肝脏病杂志,2020,28(1):21-23. [2]姜烜星,王涛,赵岩,等.血清IL-6诊断乙型肝炎肝硬化肾功能早期损害的意义[J].热带医学杂志,2020,20(3):404-406,379. [3]李萍,冷峰,徐维家.改良MDRD公式、血清肌酐、胱抑素C、β2微球蛋白及甲状旁腺素在慢性肾病早期诊断中的临床应用[J].国际检验医学杂志,2013,34(22):3013-3014,3016. [4]Schwandt A,Denkinger M,Fasching P,et al.Comparison of MDRD, CKD-EPI,and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes[J].J Diabetes Complications,2017,31(9):1376-1383. [5]Sigal SH,Amin A,Chiodo JA,et al.Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry[J].Can J Gastroenterol Hepatol,2018,27(2018):1579508. [6]Wang P,Huang G,Tam N,et al.Influence of Preoperative Sodium Concentration on Outcome of Patients With Hepatitis B Virus Cirrhosis After Liver Transplantation[J].Eur J Gastroenterol Hepatol,2016,28(10):1210-1215. [7]李文刚,徐小元.失代偿性肝硬化患者合并肾损伤与肝肾综合征的管理[J].中华肝脏病杂志,2020,28(5):381-385. [8]顾锡炳,徐月琴.肝硬化患者血钠水平与肾功能损害的关系[J].临床肝胆病杂志,2009,25(4):294-295. [9]周一萌,王岩,路丽芳,等.肝硬化患者并发肾损害危险因素的回顾性分析[J].中国现代医学杂志,2019,29(20):74-78. [10]Jia JD,Xie W,Ding HG,et al.Utility and safety of tolvaptan in cirrhotic patients with hyponatremia:A prospective cohort study[J].Ann Hepatol,2017,16(1):123-132. [11]张巍,邵明亮,苗同国,等.慢性乙型肝炎病毒感染合并急性肾损伤的发病特点及近期预后分析[J].中国现代医学杂志,2020,30(1):70-76. [12]庞连胜,赵万春.血清CysC、尿β2-MG、尿mAlb三项联合检测对肝癌及肝硬化继发早期肾功能损伤的诊断价值[J].肝脏,2019,24(6):649-652. [13]熊朝磊,顾芳,刘娟.血清胱抑素C及其估算肾小球滤过率对肝硬化患者肾功能损害的诊断价值研究[J].实用医院临床杂志,2018,15(4):171-174.

相似文献/References:

[1]冯江芳.多发性骨髓瘤患者校正血钙的临床分析[J].医学信息,2018,31(10):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
　FENG Jiang-fang.Clinical Analysis of Corrected Serum Calcium in Patients with Multiple Myeloma[J].Medical Information,2018,31(19):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
[2]唐平阳.恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的 临床疗效分析[J].医学信息,2018,31(10):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
　TANG Ping-yang.Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis[J].Medical Information,2018,31(19):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
[3]陈 欢,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者 肝功能及血脂水平分析[J].医学信息,2019,32(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
　CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute, Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Medical Information,2019,32(19):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
[4]郑莹莹.血清胱抑素C、尿β2微球蛋白联合检测在糖尿病肾损害早期诊断中的价值[J].医学信息,2019,32(01):170.[doi:10.3969/j.issn.1006-1959.2019.01.054]
　ZHENG Ying-ying.The Value of Combined Detection of Serum Cystatin C and Urinary β2 Microglobulin in the Early Diagnosis of Diabetic Renal Damage[J].Medical Information,2019,32(19):170.[doi:10.3969/j.issn.1006-1959.2019.01.054]
[5]张晓燕.中医治未病思想结合降压药物预防老年高血压患者肾损害疗效观察[J].医学信息,2019,32(06):164.[doi:10.3969/j.issn.1006-1959.2019.06.053]
　ZHANG Xiao-yan.Therapeutic Effect of Traditional Chinese Medicine Treatment and Disease Prevention Combined with Antihypertensive Drugs on Preventing Renal Damage in Elderly Patients with Hypertension[J].Medical Information,2019,32(19):164.[doi:10.3969/j.issn.1006-1959.2019.06.053]
[6]李 静.氯沙坦联合丹参酮注射液治疗高血压肾损害的疗效[J].医学信息,2019,32(16):138.[doi:10.3969/j.issn.1006-1959.2019.16.046]
　LI Jing.Efficacy of Losartan Combined with Tanshinone Injection in the Treatment of Hypertensive Renal Damage[J].Medical Information,2019,32(19):138.[doi:10.3969/j.issn.1006-1959.2019.16.046]
[7]周 煜.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的影响[J].医学信息,2019,32(22):132.[doi:10.3969/j.issn.1006-1959.2019.22.044]
　ZHOU Yu.Effect of Entecavir Combined with Microecological Preparation on Liver Function and Prognosis in Patients with Hepatitis B Cirrhosis[J].Medical Information,2019,32(19):132.[doi:10.3969/j.issn.1006-1959.2019.22.044]
[8]吕 奕,王毓麟.参麦注射液联合阿德福韦酯治疗乙肝肝硬化失代偿期的疗效[J].医学信息,2020,33(06):162.[doi:10.3969/j.issn.1006-1959.2020.06.055]
　LYU Yi,WANG Yu-lin.Effect of Shenmai Injection Combined with Adefovir Dipivoxil on Decompensation of Hepatitis B Cirrhosis[J].Medical Information,2020,33(19):162.[doi:10.3969/j.issn.1006-1959.2020.06.055]
[9]姚志伟.乙肝肝硬化患者上消化道病变胃镜检出结果分析[J].医学信息,2020,33(18):94.[doi:10.3969/j.issn.1006-1959.2020.18.030]
　YAO Zhi-wei.Analysis of the Results of Upper Gastrointestinal Lesions Detected by Gastroscopy in Patients with Hepatitis B and Liver Cirrhosis[J].Medical Information,2020,33(19):94.[doi:10.3969/j.issn.1006-1959.2020.18.030]
[10]寇 天,郝振伟,陈 曦.尿微量白蛋白/肌酐比值、血清肌酐和血清胱抑素C对老年高血压患者早期肾损害的诊断价值研究[J].医学信息,2023,36(02):103.[doi:10.3969/j.issn.1006-1959.2023.02.020]
　KOU Tian,HAO Zhen-wei,CHEN Xi.The Diagnostic Value of Urinary Albumin/Creatinine Ratio, Serum Creatinine and Serum Cystatin C in Early Renal Damage in Elderly Patients with Hypertension[J].Medical Information,2023,36(19):103.[doi:10.3969/j.issn.1006-1959.2023.02.020]

更新日期/Last Update: 1900-01-01